Effect of food and a proton pump inhibitor on the pharmacokinetics of S-1 following oral administration of S-1 in patients with advanced solid tumors

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 3, 2012, Pages 753-761

  Scheulen, Max E ^a   Saito, Kaku ^b   Hilger, Ralf A ^a   Mende, Bastian ^a   Zergebel, Christopher ^b   Strumberg, Dirk ^c  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b Taiho Pharma USA Inc   (United States)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Fluoropyrimidines; Food effect; Pharmacokinetics: advanced solid tumors; Phase I

Indexed keywords

FLUOROURACIL; GIMERACIL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; OTERACIL POTASSIUM; PROTON PUMP INHIBITOR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BREAST CANCER; COLORECTAL CANCER; CONTROLLED STUDY; DIET RESTRICTION; DRUG BIOAVAILABILITY; DRUG EXPOSURE; FEEDING; FEMALE; FOOD; FOOD DRUG INTERACTION; HUMAN; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MULTICENTER STUDY; OCULAR MELANOMA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; SOLID TUMOR; STOMACH PH; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FASTING; FEMALE; FOOD-DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; OXONIC ACID; PROTON PUMP INHIBITORS; TEGAFUR; TREATMENT OUTCOME;

EID: 84859756288     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1761-2     Document Type: Article

References (21)

1. Shirasaka T, Shimamato Y, Ohshimo H et al (1996) Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumour selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7:548-557 (Pubitemid 26276346)
2. Anttila MI, Sotaniemi EA, Kairaluoma MI et al (1983) Pharmacokinetics of Ftorafur after intravenous and oral administration. Cancer Chemother Pharmacol 10:150-153 (Pubitemid 13028309)
3. Diasio RB, Harris BE (1989) Clinical pharmacology of 5- fluorouracil. Clin Pharmacokinet 16:215-237
4. Iyer L, Ratain MJ (1999) 5-Fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy. Cancer Investig 17:494-506 (Pubitemid 29458122)
5. Tatsumi K, Fukushima M, Shirasaka T et al (1987) Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extracts. Jpn J Cancer Res 78(7):748-755 (Pubitemid 17132408)
6. Shirasaka T, Shimamoto Y, Fukushima M (1993) Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 53(17):4004-4009 (Pubitemid 23267702)
7. Takechi T, Nakano K, Uchida J et al (1997) Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother Pharmacol 39(3):205-211 (Pubitemid 26414256)
8. Shirasaka T, Shimamoto Y, Kato T et al (1998) Invention of a tumor-selective 5-fluorouracil derivative named S-1 by biochemical modulation of 5-fluorouracil [in Japanese]. Jpn J Cancer Chemother 25:371-384
9. Kato T, Shimamoto Y, Uchida J (2001) Possible regulation of 5-fluorouracil-induced neuro- and oral toxicities by two biochemical modulators consisting of S-1, a new oral formulation of 5- fluorouracil. Anticancer Res 21:1705-1712 (Pubitemid 32728903)
10. The effect of food on the pharmacokinetics of S-1 after single administration in human plasma of patients with solid tumors (2001) Clinical Study Report (Taiho Pharmaceutical Co., Ltd.)
11. Savarino V, Mela GS, Zentilin G et al (1998) Comparison of 24-h control of gastric acidity by three different dosages of pantoprazole in patients with duodenal ulcer. Aliment Pharmacol Ther 12:1241-1247 (Pubitemid 28565965)
12. Tutuian R, Katz PO, Bochenek W et al (2002) Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers. Aliment Pharmacol Ther 16:829-836 (Pubitemid 34407533)
13. Sakuramoto S, Sasako M, Yamaguchi T, ACTS-GC Group et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357(18):1810-1820 (Pubitemid 350044801)
14. Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9(3): 215-221
15. Kato K, Muro K, Yasui H et al (2009) The FIRIS study; a phase III trial of 5FU/l-leucovorin/irinotecan (FOLFIRI) versus irinotecan/S-1 (IRIS) as 2nd-line chemotherapy for metastatic colorectal cancer (mCRC) [FIRIS study group]. Eur J Cancer Suppl 7(2):324
16. Ajani JA, Rodriguez W, Bodoky G et al (2010) Multicenter phase III comparison of cisplatin/S-1 with cisplatin/infusional fluorouracil in advanced gastric or gastroesophageal adenocarcinoma study: the FLAGS trial. J Clin Oncol 28(9):1547-1553
17. Yoshioka H, Okamoto I, Morita S et al (2010) Randomized phase III study of carboplatin plus S-1 compared with carboplatin plus paclitaxel as first-line chemotherapy in advanced non-small cell lung cancer (WJTOG3605). J Clin Oncol 28:7s suppl; abstr 7530
18. Hirata K, Horikoshi N, Aiba K et al (1999) Pharmacokinetic study of S-1, a novel oral fluorouracil antitumor drug. Clin Cancer Res 5(8):2000-2005 (Pubitemid 29399250)
19. Yoshida K, Ikeda K, Yoshisue K et al. (2011) Population pharmacokinetic (PPK) analysis for 5-FU, tegafur (FT), gimeracil (CDHP), and oteracil potassium (Oxo) in the eight clinical studies of S-1 in Western patients with advanced solid tumors. J Clin Oncol 29, (suppl 4; abstr 53)
20. Peters GJ, Noordhuis P, Van Groeningen CJ et al (2004) The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors. Clin Cancer Res 15(10):4072-4076 (Pubitemid 38812484)
21. Reigner B, Verweij J, Dirix L et al (1998) Effect of food on the pharmacokinetics of capecitabine and its metabolites following oral administration in cancer patients. Clin Cancer Res 4(4):941-948 (Pubitemid 28183395)